- Home
- CRBP vs TIL Comparison
CRBP vs TIL Comparison
Compare CRBP & TIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRBP
- TIL
- Stock Information
- Founded
- CRBP 2009
- TIL 2018
- Country
- CRBP United States
- TIL United States
- Employees
- CRBP N/A
- TIL N/A
- Industry
- CRBP Biotechnology: Pharmaceutical Preparations
- TIL Biotechnology: Pharmaceutical Preparations
- Sector
- CRBP Health Care
- TIL Health Care
- Exchange
- CRBP Nasdaq
- TIL Nasdaq
- Market Cap
- CRBP 114.8M
- TIL 177.1M
- IPO Year
- CRBP N/A
- TIL 2021
- Fundamental
- Price
- CRBP $9.37
- TIL $25.78
- Analyst Decision
- CRBP Strong Buy
- TIL Buy
- Analyst Count
- CRBP 10
- TIL 6
- Target Price
- CRBP $53.22
- TIL $120.50
- AVG Volume (30 Days)
- CRBP 91.8K
- TIL 138.2K
- Earning Date
- CRBP 11-06-2025
- TIL 11-12-2025
- Dividend Yield
- CRBP N/A
- TIL N/A
- EPS Growth
- CRBP N/A
- TIL N/A
- EPS
- CRBP N/A
- TIL N/A
- Revenue
- CRBP N/A
- TIL N/A
- Revenue This Year
- CRBP N/A
- TIL N/A
- Revenue Next Year
- CRBP $220.04
- TIL N/A
- P/E Ratio
- CRBP N/A
- TIL N/A
- Revenue Growth
- CRBP N/A
- TIL N/A
- 52 Week Low
- CRBP $4.64
- TIL $10.80
- 52 Week High
- CRBP $56.93
- TIL $76.13
- Technical
- Relative Strength Index (RSI)
- CRBP 47.64
- TIL 47.60
- Support Level
- CRBP $9.42
- TIL $22.67
- Resistance Level
- CRBP $9.73
- TIL $33.83
- Average True Range (ATR)
- CRBP 0.49
- TIL 2.51
- MACD
- CRBP -0.09
- TIL -0.43
- Stochastic Oscillator
- CRBP 19.37
- TIL 27.86
About CRBP Corbus Pharmaceuticals Holdings Inc.
Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.
About TIL Instil Bio Inc.
Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.